1014695-10-3

Basic information

• Product Name: 1-(2,2-dimethylpropyl)-4-piperidinamine(SALTDATA: HCl)
• Synonyms: 1-(2,2-dimethylpropyl)-4-piperidinamine(SALTDATA: HCl);1-(2,2-dimethylpropyl)-4-piperidinamine
• CAS NO: 1014695-10-3
• Molecular Formula: C₁₀H₂₂N₂
• Molecular Weight: 170.29508
• Mol File: 1014695-10-3.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1-(2,2-dimethylpropyl)-4-piperidinamine(SALTDATA: HCl)(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(2,2-dimethylpropyl)-4-piperidinamine(SALTDATA: HCl)(1014695-10-3)
• EPA Substance Registry System: 1-(2,2-dimethylpropyl)-4-piperidinamine(SALTDATA: HCl)(1014695-10-3)

Safety Data

• Hazardous Substances Data: 1014695-10-3(Hazardous Substances Data)

Usage

General Description

1-(2,2-dimethylpropyl)-4-piperidinamine, also known as HCl, is a chemical compound commonly used as an intermediate in the synthesis of various pharmaceuticals. It is a piperidine derivative with a molecular formula of C12H24ClN and a molecular weight of 215.78 g/mol. 1-(2,2-dimethylpropyl)-4-piperidinamine(SALTDATA: HCl) exists as a white to off-white crystalline powder and is typically administered as a prescription medication. It acts as a selective norepinephrine reuptake inhibitor and is commonly used in the treatment of depression, anxiety, and other mood disorders. Despite its therapeutic benefits, it is important to use this chemical under the supervision of a qualified healthcare professional due to potential side effects and drug interactions.

Upstream product

• 220394-97-8 4-(benzyloxycarbonylamino)-1-(tert-butoxycarbonyl)piperidine 
• 87120-72-7 1-(tert-butoxycarbonyl)-4-aminopiperidine 
• 182223-54-7 piperidin-4-ylcarbamic acid benzyl ester 

Relevant articles and documents

Discovery of 2-substituted 1H-benzo[d]immidazole-4-carboxamide derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors with in?vivo anti-tumor activity

Novel 1H-benzo[d]immidazole-4-carboxamide derivatives bearing five-membered or six-membered N-heterocyclic moieties at the 2-position were designed and synthesized as PARP-1 inhibitors. Structure-activity relationships were conducted and led to a number of potent PARP-1 inhibitors having IC50 values in the single or double digit nanomolar level. Some potent PARP-1 inhibitors also had similar inhibitory activities against PARP-2. Among all the synthesized compounds, compound 10a and 11e displayed strong potentiation effects on temozolomide (TMZ) in MX-1?cells (PF50?=?7.10, PF50?=?4.17). In?vivo tumor growth inhibition was investigated using compound 10a in combination with TMZ, and it was demonstrated that compound 10a could strongly potentiate the cytotoxicity of TMZ in MX-1 xenograft tumor model. Two co-crystal structures of compounds 11b and 15e complexed with PARP-1 were achieved and demonstrated a unique binding mode of these benzo-imidazole derivatives.

5-SUBSTITUTED INDAZOLE-3-CARBOXAMIDES AND PREPARATION AND USE THEREOF

Indazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of an indazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, Alzheimer's disease, lung disease, fibrotic disorders, cartilage (chondral) defects, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, and neurological conditions/disorders/diseases linked to overexpression of DYRK1A.